A Mechanistic Clinical Trial Using ( R )- Versus (S )-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction
- 1 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (10) , e010713
Abstract
Background: Experimental data suggest ryanodine receptor-mediated intracellular calcium leak is a mechanism for atrial fibrillation (AF), but evidence in humans is still needed. Propafenone is composed of two enantiomers that are equally potent sodium-channel blockers; however, (R )-propafenone is an ryanodine receptor inhibitor whereas (S )-propafenone is not. This study tested the hypothesis that ryanodine receptor inhibition with (R )-propafenone prevents induction of AF compared to (S )-propafenone or placebo in patients referred for AF ablation. Methods: Participants were randomized 4:4:1 to a one-time intravenous dose of (R )-propafenone, (S )-propafenone, or placebo. The study drug was given at the start of the procedure and an AF induction protocol using rapid atrial pacing was performed before ablation. The primary endpoint was 30 s of AF or atrial flutter. Results: A total of 193 participants were enrolled and 165 (85%) completed the study protocol (median age: 63 years, 58% male, 95% paroxysmal AF). Sustained AF and/or atrial flutter was induced in 60 participants (84.5%) receiving (R )-propafenone, 60 (80.0%) receiving (S )-propafenone group, and 12 (63.2%) receiving placebo. Atrial flutter occurred significantly more often in the (R )-propafenone (N=23, 32.4%) and (S )-propafenone (N=26, 34.7%) groups compared to placebo (N=1, 5.3%, P =0.029). There was no significant difference between (R )-propafenone and (S )-propafenone for the primary outcome of AF and/or atrial flutter induction in univariable ( P =0.522) or multivariable analysis ( P =0.199, adjusted for age and serum drug level). Conclusions: There is no difference in AF inducibility between (R )-propafenone and (S )-propafenone at clinically relevant concentrations. These results are confounded by a high rate of inducible atrial flutter due to sodium-channel blockade. Registration: https://clinicaltrials.gov ; Unique Identifier: NCT02710669.Keywords
This publication has 29 references indexed in Scilit:
- Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgeryCochrane Database of Systematic Reviews, 2013
- Inducibility of Atrial Fibrillation and Flutter Following Pulmonary Vein AblationJournal of Cardiovascular Electrophysiology, 2013
- Calcium Leak Through Ryanodine Receptors Leads to Atrial Fibrillation in 3 Mouse Models of Catecholaminergic Polymorphic Ventricular TachycardiaCirculation Research, 2012
- An Introduction to Murine Models of Atrial FibrillationFrontiers in Physiology, 2012
- Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrinJournal of Molecular and Cellular Cardiology, 2011
- Recent advances in the molecular pathophysiology of atrial fibrillationJournal of Clinical Investigation, 2011
- Inhibition of Cardiac Ca 2+ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular TachycardiaCirculation: Arrhythmia and Electrophysiology, 2011
- Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillationHeart Rhythm, 2008
- Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillationThe American Journal of Cardiology, 1998
- Restoration of sinus rhythm in atrial fibrillation of recent onset using intravenous propafenoneAmerican Heart Journal, 1991